For following the competition: what moved in each program, several studies read as one move.
- Lutetium Lu 177 Ludotadipep
- Teverelix DP
- NSD2 Inhibitor KTX-2001
Mondays · ranked, phase 3 first · readouts ahead · See a sample brief
Add Prostatic Diseases to watchlistEvery Monday by email · turn it off any timePro · free during the beta